Toggle Nav

AZ 628

In stock
Catalog No.
A8371
Raf kinases,potent and ATP-competitive
Grouped product items
SizePriceStock Qty
10mM (in 1mL DMSO)
$77.00
In stock
5mg
$70.00
In stock
10mg
$110.00
In stock
25mg
$220.00
In stock
50mg
$360.00
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

AZ628 is a potent and newly discorvered inhibitor of BRAF, c-Raf-1 and BRAFV600E with IC50 values of 105 nM, 29 nM and 34 nM, respectively. This compound prevents CRAF activation through persistently occupying the ATP-binding site of Raf kinase. Specificity profile suggests that AZ628 also inhibits activation of other tyrosine protein kinases such as DDR2, VEGFR2, Lyn, Flt1, FMS and others.

Raf kinases a family of three serine/threonine-specific protein kinases and participate in the RAS-RAF-MEK-ERK signal transduction cascade, also known as the mitogen-activated protein kinase (MAPK) cascade. The activation of MAPK signaling leads to different cellular response such as cell proliferation, apoptosis and inflammation.

AZ628 has the potent anti-tumor activity. In human colon and melanoma-derived cell line that carries the recurrent V600E activating BRAF mutation, AZ628 was shown to inhibit anchorage-dependent and -independent growth, induce cell cycle arrest, and cause apoptosis [1]. AZ628 may be antiangiogenic due to inhibition of VEGFR2 [2].

Generation of melanoma cell line clones is obtained resistance to the RAF kinase inhibitor AZ628. Resistance to AZ628 is connected with raised levels of the RAF downstream effector p-ERK1/2. ERK1/2 initiation in AZ628-resistant clones is interceded by MEK. Supported multiplication of AZ628-resistant clones is to a great extent autonomous of BRAF kinase action. AZ628-resistant clones express elevated CRAF. Survival of AZ628-safe cells is subject to CRAF [1].

References:
1.  Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 2008,68:4853-4861.
2.  Khazak V, Astsaturov I, Serebriiskii IG, Golemis EA. Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets 2007,11:1587-1609.

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
M.Wt451.53
Cas No.878739-06-1
FormulaC27H25N5O2
SynonymsAZ-628; AZ628
Solubility≥22.6mg/mL in DMSO
Chemical Name3-(2-cyanopropan-2-yl)-N-[4-methyl-3-[(3-methyl-4-oxoquinazolin-6-yl)amino]phenyl]benzamide
SDFDownload SDF
Canonical SMILESCC1=C(C=C(C=C1)NC(=O)C2=CC(=CC=C2)C(C)(C)C#N)NC3=CC4=C(C=C3)N=CN(C4=O)C
Shipping ConditionEvaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

Biological Activity

Description AZ628 is a new inhibitor of BRAF, BRAFV600E and c-Raf-1 with IC50 values of 105 nM, 34 nM and 29 nM,respectively.
Targets C-Raf-1 B-Raf (V600E) B-Raf      
IC50 29 nM 34 nM 105 nM      

Quality Control

Quality Control & MSDS

View current batch:

Chemical structure

AZ 628